AdaptHealth has significantly lowered its sales guidance for fiscal year 2026, reducing the outlook from a range of $3.450B-$3.520B to $2.850B-$2.890B. This substantial downward revision, representing an approximate 18% cut at the midpoint, is a major negative catalyst for the company and will likely lead to a significant negative market reaction.
AdaptHealth (AHCO) announced a substantial reduction in its FY2026 sales guidance, lowering the projected range from $3.450B-$3.520B to $2.850B-$2.890B. This represents an approximate 18% decrease from the previous guidance and is significantly below the analyst consensus of $3.488B. This news is a major negative catalyst as it indicates a much weaker long-term revenue outlook than previously anticipated, likely due to operational challenges, competitive pressures, or changes in market demand. Traders should expect a sharp negative reaction in AHCO's stock price in the short term, as this revision will necessitate a re-evaluation of the company's future growth prospects and valuation. The key risk for traders is the potential for further downward revisions or a prolonged period of underperformance.